

## **INTERVIEW AND WEBINAR PUBLISHED ON ANNEXIN'S ONGOING PHASE 2A STUDY IN DIABETIC RETINOPATHY AND RETINAL VEIN OCCLUSION**

**Annexin Pharmaceuticals AB today announces that Redeye has published an interview with the company's CEO Anders Haegerstrand and CSO/CMO Anna Frostegård regarding the ongoing clinical Proof of Concept phase 2a study with the drug candidate ANXV in the eye diseases diabetic retinopathy (DR) and retinal vein occlusion (RVO) and a summary of the year. A webinar about RVO and the Annexin study conducted by Professor Paulo-Eduardo Stanga is also available.**

Annexin has recently announced that the first two patients have been dosed in the ongoing Phase 2a study, which is being conducted at The Retina Clinic in London under the leadership of Professor Paulo-Eduardo Stanga. In the interview, Anders Haegerstrand and Anna Frostegård give an insight into why the study is important, inform about the chosen study design and the type of data that can be expected to show within DR and RVO, as well as how the company's partnership discussions are progressing.

The interview can be seen here: [Redeye interview](#)

Recently, Professor Paulo-Eduardo Stanga at The Retina Clinic held a webinar, *Retinal Vein Occlusion: Clinical Features, Current Management, & Future Developments*, where he describes RVO and reviews ANXV as a potential treatment for RVO and the ongoing phase 2a study. Information about Annexin's study begins at 15:30 minutes into the video.

The webinar can be viewed here: [Retinal Vein Occlusion: Clinical Features, Current Management, & Future Developments](#)

**For further information, please contact:**

Anders Haegerstrand, CEO

Phone: +46 (0)70 575 50 37

Mail: [anders.haegerstrand@annexinpharma.com](mailto:anders.haegerstrand@annexinpharma.com)

**About Annexin Pharmaceuticals AB**

Annexin Pharmaceuticals AB is a leading biotechnology company in the Annexin A5 field for the treatment of various diseases. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for treatment of patients with injuries and inflammation of the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment of diseases with Annexin A5 and for production of Annexin A5. The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company's Certified Adviser.

**Attachments**

**Interview and webinar published on Annexin's ongoing Phase 2a study in diabetic retinopathy and retinal vein occlusion**